# US 2022/0008524 A1 · Vaccination with microvesicles derived from tumour cells for cancer treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0008524 A1
- Document ID: US20220008524A1
- Status: Published application
- Kind: A1
- Application number: 17/264,551
- Filed: 2018-07-31
- Published: 2022-01-13
- Earliest claimed: 2018-07-31
- Inventors: Benjamin Pineda Olvera; Veronica Perez De La Cruz
- Web page: https://patentgrep.com/patent/US20220008524A1

## CPC

- A61K 39/0011: {Cancer antigens}
- A61K 35/13: Tumour cells, irrespective of tissue of origin (tumour vaccines A61K39/00)
- A61K 41/00: Medicinal preparations obtained by treating materials with wave energy or particle radiation {; Therapies using these preparations}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C12N 5/0693: {Tumour cells; Cancer cells}
- G01N 33/5076: {involving cell organelles, e.g. Golgi complex, endoplasmic reticulum}
- G01N 33/575: for cancer
- A61K 2039/5152: {Tumor cells}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/64: {characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to microvesicles derived from natural tumor cells and tumor cells produced in vitro under a stress stimulus, such as radiation, which can be used in an effective manner as a therapeutic vaccine for cancer. The invention also relates to a therapeutic vaccine formulation containing the microvesicles, processes for the preparation and medical use thereof as a therapeutic vaccine to stimulate the antitumor immune system and treat cancer.

## Claims

### Claim 1

Microvesicles derived from in vitro irradiated neoplastic cells, characterized by having a mean size between 200 and 400 nm.

### Claim 2 (depends on 1)

The microvesicles according to claim 1, wherein the mean size is of about 340 nm.

### Claim 3 (depends on 1)

The microvesicles according to claim 1, wherein the radiation dose applied to obtain the microvesicles is between 45 and 55 Gy.

### Claim 4 (depends on 3)

The microvesicles according to claim 3, wherein the radiation dose applied to obtain the microvesicles is 50 Gy.

### Claim 5 (depends on 1)

The microvesicles according to claim 1, further characterized in that they do not contain Nuclear Factor of Activated T Cell 4 (NFATC4).

### Claim 6 (depends on 1)

The microvesicles according to claim 1, further characterized in that they comprise HSP70 and/or HSP90 heat shock proteins.

### Claim 7 (depends on 1)

The microvesicles according to claim 1, further characterized in that the outer membrane of the microvesicles contains phosphatidylserine.

### Claim 8 (depends on 1)

The microvesicles according to claim 1, further characterized in that they are positive to annexin V.

### Claim 9 (depends on 1)

The microvesicles according to claim 1, for use alone or in combination with one or more antineoplastic treatments in the treatment or prophylaxis of malignant neoplasms, or in the modulation of the antitumor immune response.

### Claim 10 (depends on 9)

The microvesicles for use according to claim 9, wherein the one or more antineoplastic treatments are selected from the group consisting of: chemotherapy, radiotherapy, immunotherapy, or combinations thereof.

### Claim 11 (depends on 1)

The microvesicles according to claim 1, for use as prognostic or diagnostic markers of neoplasms.

### Claim 12 (depends on 1)

A therapeutic vaccine for cancer, characterized in that it comprises the microvesicles according to claim 1, along with pharmaceutically acceptable additives.

### Claim 13 (depends on 1)

A process to prepare the microvesicles according to claim 1, wherein said process comprises the step of irradiating neoplastic cells at a radiation dose of between 45 and 55 Gy.

### Claim 14 (depends on 13)

The process according to claim 13 wherein the radiation dose is 50 Gy.

### Claim 15 (depends on 12)

A process to prepare the therapeutic vaccine according to claim 12, wherein said process comprises the step of irradiating neoplastic cells at a radiation dose of between 45 and 55 Gy.

### Claim 16 (depends on 15)

The process according to claim 15 wherein the radiation dose is 50 Gy.
